NASDAQ: AGRXAgile Therapeutics Inc Stock
$2.59+0.19 (+7.92%)
Updated Oct 2, 2023
AGRX Price
$2.59
Fair Value Price
$2.70
Market Cap
$4.99M
52 Week Low
$1.65
52 Week High
$16.00
P/E
0.05x
P/B
-0.41x
P/S
0.32x
PEG
N/A
Dividend Yield
N/A
Revenue
$16.31M
Earnings
-$10.63M
Gross Margin
54.7%
Operating Margin
-51.58%
Profit Margin
-65.1%
Debt to Equity
-2.04
Operating Cash Flow
-$28M
Beta
0.95
Next Earnings
Nov 6, 2023
Ex-Dividend
N/A
Next Dividend
N/A
AGRX Overview
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AGRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AGRX ($2.59) is undervalued by 3.98% relative to our estimate of its Fair Value price of $2.70 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AGRX ($2.59) is not significantly undervalued (3.98%) relative to our estimate of its Fair Value price of $2.70 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AGRX is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AGRX due diligence checks available for Premium users.
Be the first to know about important AGRX news, forecast changes, insider trades & much more!
AGRX News
Valuation
AGRX fair value
Fair Value of AGRX stock based on Discounted Cash Flow (DCF)
Price
$2.59
Fair Value
$2.70
Undervalued by
3.98%
AGRX ($2.59) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AGRX ($2.59) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AGRX is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AGRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.05x
Industry
26.4x
Market
12.38x
AGRX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AGRX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
AGRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.41x
Industry
1.97x
AGRX's financial health
Profit margin
Revenue
$5.5M
Net Income
-$3.8M
Profit Margin
-69.2%
AGRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AGRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$12.6M
Liabilities
$24.7M
Debt to equity
-2.04
AGRX's short-term liabilities ($15.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AGRX's short-term assets ($11.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AGRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AGRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.5M
Investing
$0.0
Financing
$6.9M
AGRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AGRX vs Pharmaceutical Stocks
Agile Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.